TuHURA Biosciences, Inc./NV financial data

Symbol
HURA on Nasdaq
Location
10500 University Center Dr., Suite 110, Tampa, FL
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 146 % -30.5%
Debt-to-equity 56.4 %
Return On Equity -193 % -150%
Return On Assets -123 % +59.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 51.3M shares
Common Stock, Shares, Outstanding 51.3M shares +21.9%
Entity Public Float 14.9M USD
Common Stock, Value, Issued 51.3K USD +2463%
Weighted Average Number of Shares Outstanding, Basic 50.7M shares +316%
Weighted Average Number of Shares Outstanding, Diluted 50.7M shares +316%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Research and Development Expense 18.5M USD +94.9%
General and Administrative Expense 10.9M USD +210%
Nonoperating Income (Expense) 179K USD +84.5%
Net Income (Loss) Attributable to Parent -29.3M USD -75.3%
Earnings Per Share, Basic 0 USD/shares +78.9%
Earnings Per Share, Diluted 0 USD/shares +74.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.7M USD -10.7%
Other Assets, Current 806K USD
Assets, Current 3.5M USD +0.6%
Property, Plant and Equipment, Net 295K USD -55%
Operating Lease, Right-of-Use Asset 82.7K USD
Goodwill 13.6M USD
Other Assets, Noncurrent 33.8K USD
Assets 25.7M USD +521%
Accounts Payable, Current 4.13M USD +121%
Accrued Liabilities, Current 1.21M USD +261%
Liabilities, Current 8.83M USD +291%
Operating Lease, Liability, Noncurrent 42.7K USD
Other Liabilities, Noncurrent 85K USD
Liabilities 8.92M USD +265%
Accumulated Other Comprehensive Income (Loss), Net of Tax 21K USD 0%
Retained Earnings (Accumulated Deficit) -134M USD +17.1%
Stockholders' Equity Attributable to Parent 16.8M USD
Liabilities and Equity 25.7M USD +521%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.74M USD -23.6%
Net Cash Provided by (Used in) Financing Activities -548K USD -112%
Net Cash Provided by (Used in) Investing Activities -1.15M USD
Common Stock, Shares Authorized 200M shares +167%
Common Stock, Shares, Issued 51.3M shares +3124%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.44M USD -908%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.7M USD -86.2%
Deferred Tax Assets, Valuation Allowance 46.5M USD +118%
Deferred Tax Assets, Gross 46.5M USD +118%
Depreciation 68K USD -27.6%
Payments to Acquire Property, Plant, and Equipment 42.7K USD
Property, Plant and Equipment, Gross 2.43M USD
Operating Lease, Liability, Current 84.3K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 43.4K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 43.4K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Deferred Tax Assets, Operating Loss Carryforwards 25.1M USD +125%
Preferred Stock, Shares Authorized 5M shares 0%
Operating Lease, Payments 43K USD +30.3%
Depreciation, Depletion and Amortization 14.1K USD -59%
Deferred Tax Assets, Net of Valuation Allowance 51.2K USD -21.8%
Share-based Payment Arrangement, Expense 1.42M USD +326%
Interest Expense 16.5K USD -99.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%